Medtronic (MDT) Q1 2027 earnings review
Broad-Based Strength and Extra Week Drive Revenue Beat; Guidance Raised
Medtronic delivered a robust Q1 FY27, with revenue growing 13.7% organically to $9.76 billion, although an estimated $570 million of this came from an extra selling week. Earnings quality remains strong, with non-GAAP EPS up 15.1% to $1.45, beating expectations and outpacing revenue growth. Cardiac Ablation Solutions (CAS) continues to be the standout growth engine, surging 88%. The strong start, coupled with disciplined operational execution, gave management the confidence to raise full-year organic revenue and EPS guidance.
🐂 Bull Case
Growth is not isolated to one segment. All four major portfolios delivered 9%+ organic growth, with Cardiovascular (+18.9%) and Diabetes (+14.9%) leading the charge.
The Cardiac Ablation Solutions (CAS) segment grew a staggering 88%. The Pulsed Field Ablation (PFA) rollout continues to take significant market share and scale rapidly.
🐻 Bear Case
The 53rd week added roughly $570 million to the top line. Excluding this, underlying organic growth was closer to 7.4%—still strong, but less euphoric than the 13.7% headline suggests.
Gross margins remain constrained by the high volume of lower-margin capital systems placed during the CAS rollout, compounded by ongoing international tariff headwinds.
⚖️ Verdict: 🟢
Bullish. Even after stripping out the 53rd-week benefit, the core business is accelerating. Management's ability to drive 15% EPS growth while funding massive product launches proves their operational leverage story is materializing.
Key Themes
Cardiac Ablation Solutions (CAS) Engine Roars
CAS is Medtronic's premier growth driver, accelerating to 88% organic growth in Q1, up from 78% in Q4 and 80% in Q3 of FY26. The rollout of the Affera Mapping and Ablation System and the Sphere-9 Catheter (which recently received expanded CE Mark) is aggressively capturing share in the $13B+ electrophysiology market.
Extra Week Obscures True Momentum
Medtronic reported an incredible 13.7% organic revenue growth, but investors must account for the 53rd week that fell in Q1. This extra week contributed an estimated $570 million to revenue. Without it, underlying organic growth would have been approximately 7.4%. While still an acceleration from Q4's 6.6%, the headline number drastically overstates the near-term trajectory.
Diabetes Inflection Confirmed
The Diabetes business (MiniMed) is accelerating, posting 14.9% organic growth in Q1, up from 8.1% in Q4 FY26. This turnaround validates the market traction of new sensors like Simplera Sync and Instinct. This momentum is critical as the company prepares to spin off the unit by the end of calendar 2026, which is expected to immediately lift Medtronic's overall gross and operating margins.
Aggressive Tuck-In M&A and Partnerships
Management continues to deploy capital aggressively to expand its total addressable market. In Q1 alone, Medtronic closed acquisitions of Scientia Vascular and SPR Therapeutics, announced a strategic investment in Pi-Cardia (leaflet modification), and formed a partnership with Cornerstone Robotics to scale its surgical presence globally.
Capital Equipment Mix Pressuring Margins
Despite a massive beat on the top and bottom lines, Non-GAAP operating margins only expanded by 10 basis points YoY (to 23.7%). The drag is primarily driven by business mix—specifically, the high proportion of capital equipment sales (mapping systems) required to fuel the CAS/PFA catheter launch. This margin drag will persist until the installed base matures and high-margin recurring catheter sales outpace hardware placements.
Other KPIs
Accelerating dramatically. Free Cash Flow more than doubled from $584 million in Q1 FY26 to $1.29 billion in Q1 FY27. This was driven by a $705 million increase in operating cash flows, reflecting superior working capital management, particularly a sharp normalization in inventory levels compared to the prior year.
Accelerating. Medical Surgical grew 10.2% organically, a significant step up from 5% in Q4 FY26 and 1.3% in Q2 FY26. Acute Care & Monitoring led the way with 14.2% organic growth, proving the segment has durable demand extending beyond previous quarters' post-COVID normalization.
Accelerating. Neuroscience delivered 9.3% organic growth, stepping up from 3% in Q4 FY26. Cranial and Spinal Technologies was the standout (+13%), bolstered by low-20s growth in enabling technologies like the Stealth AXiS robotic system. Pelvic Health also contributed meaningfully (+15%), driven by the Altaviva rollout.
Guidance
Accelerating. Raised by 50 basis points from the prior 6.75% - 7.25% range. This implies a significant acceleration from FY26's 5.8% organic growth, heavily supported by the CAS launch, the Diabetes turnaround, and the inclusion of the 53rd week.
Accelerating. Raised from the prior range of $5.90 - $6.00. The new midpoint of $5.97 implies approximately 7.9% YoY growth over FY26's $5.53, confirming management's commitment to high-single-digit EPS expansion despite tariff and M&A dilution headwinds.
Key Questions
CAS Margin Inflection Timing
CAS is growing 88% organically, but capital equipment sales are diluting overall gross margins. When do you model the inflection point where high-margin catheter pull-through overtakes hardware placements to become a net positive for gross margin?
TAVR Stabilization vs Recovery
Last quarter, management noted U.S. TAVR softness had stabilized. With Cardiovascular growing nearly 19% organically this quarter, has the Structural Heart business transitioned from stabilized back to active market share expansion?
Post-Extra Week Run Rate
Excluding the estimated $570 million benefit from the extra week, organic growth was roughly 7.4%. As we model Q2 and Q3 without this timing benefit, how should we expect sequential growth cadence to look given the tougher comps?
Hugo RAS Go-to-Market Strategy
With the new Cornerstone Robotics partnership and FDA clearance for Touch Surgery Aide, how does this shift the commercialization timeline and geographic rollout strategy for the Hugo surgical robotics ecosystem?